How are you taking part in this consultation?

You will not be able to change how you comment later.

You must be signed in to answer questions

  • Question on Consultation

    Has all of the relevant evidence been taken into account?

  • Question on Consultation

    Are the summaries of clinical and cost effectiveness reasonable interpretations of the evidence?

  • Question on Consultation

    Are the recommendations sound and a suitable basis for guidance to the NHS?

  • Question on Consultation

    Are there any aspects of the recommendations that need particular consideration to ensure we avoid unlawful discrimination against any group of people on the grounds of race, gender, disability, religion or belief, sexual orientation, age, gender reassignment, pregnancy and maternity?
The content on this page is not current guidance and is only for the purposes of the consultation process.

Talquetamab for treating relapsed and refractory multiple myeloma after 3 or more treatments

Closed for comments This consultation ended on at   Request commenting lead permission

2 Information about talquetamab

Marketing authorisation indication

2.1

Talquetamab (Talvey, Johnson & Johnson Innovative Medicine) is indicated 'as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least 3 prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody and have demonstrated disease progression on the last therapy'.

Price

2.3

The list price for talquetamab is £326.41 per 3-mg vial and £4,352.00 per 40-mg vial (excluding VAT, BNF online accessed August 2025).

2.4

The company has a commercial arrangement, which would have applied if talquetamab had been recommended.

Carbon Reduction Plan

2.5

Information on the Carbon Reduction Plan for UK carbon emissions for Johnson & Johnson Innovative Medicine will be included here when guidance is published.